Cic edizioni internazionali
Clinical Cases in mineral and bone metabolism

Pain from osteoporotic fractures: rationale of therapeutic options

Mini-Review, 36 - 40
doi: 10.11138/ccmbm/2017.15.1.036
Tag this article
Abstract
Full text PDF
Bone fractures are the most important cause of severe acute pain in osteoporosis, which is later often followed by chronic musculoskeletal pain due to dorsal kyphosis, exaggerated lordosis or compression of nerve roots or spinal cord. The functional stress on spinal muscles and ligaments results in the development of chronic back pain and impaired mobility. Injured structures in the lumber spine can also produce referred pain or a true radicular pain.
Drugs against osteoporosis may have some analgesic effects, as has been shown for denosumab or bisphosphonates like pamidronate. Similar results have been obtained with calcitonin, which is no longer available for the treatment of osteoporosis. Selective estrogen receptor modulators like raloxifene and the anabolic drug teriparatide can also reduce osteoporotic pain and augment fracture healing.
The vicious circle of osteoporotic pain, immobility, muscle atrophy and enhanced osteoporosis has to be interrupted by an effective multimodal pain management. Beside the treatment of osteoporosis and fractures, analgesic drugs play a major role in restoring physical functioning and mobility. The mainstay in pain management of osteoporotic fractures is the WHO 3-step analgesic ladder with the combined use of non-opioids (NSAIDs, paracetamol) with weak opioids like tramadol for mild to moderate pain, or strong opioids like morphine, hydromorphone, oxycodone, buprenorphine, fentanyl or tapentadol for moderate to severe pain. The combination of nonopioids with oral controlled release (CR) strong opioids or prolonged release (PR) tapentadol provides excellent analgesia even in severe pain from osteoporotic fractures. This is also true for transdermal therapeutic systems containing fentanyl or buprenorphine (skin patches).
There are differences in the relative fracture risk of opioids, which is highest with fentanyl and lowest with buprenorphine. Some opioids influence the endocrine system, particularly the sex hormones, and lowered testosterone and estrogen levels finally reduce bone
density. Tapentadol is an exception, which acts simultaneously as a μ-opioid receptor agonist (MOR) and a noradrenalin reuptake inhibitor (NRI). It has minor effects on the endocrine system and sex hormones and should therefore be favored for long-term treatment of osteoporosis pain. The synergism between its two analgesic mechanisms improves analgesia and reduces adverse events.
In conclusion, the standard treatment of acute and chronic pain after osteoporotic fracture is a multimodal analgesic therapy including non-opioids, opioids, mobilization and rehabilitation. Opioids with minor effects on
the endocrine system and bone density, such as buprenorphine or tapentadol, should be preferred for long-term pain management in these patients.

Vol. XV (No. 1) 2018 January - April

  1. From the Editor-in-Chief
    Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.007
  2. The use of null-hypothesis significance testing: issues and solutions
    Gronchi G., Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.009
  3. Role of Mediterranean diet in bone health
    Migliaccio S., Marrocco C., Mocini E., Lenzi A., Greco E.A.
    doi: 10.11138/ccmbm/2017.15.1.016
  4. The Mediterranean diet for bone health in osteoporosis. Children and adolescents
    Pampaloni B., Quattrini S., Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.019
  5. Parmigiano Reggiano cheese: a super-food for bone health
    Pampaloni B., Cianferotti L., Ciampi V., Nocetti M., Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.029
  6. Pain from osteoporotic fractures: rationale of therapeutic options
    Hans G. Kress
    doi: 10.11138/ccmbm/2017.15.1.036
  7. New therapeutic strategies in the management of chronic pain related to osteoporosis
    Arghetti S., Magenta P., Racagni M.
    doi: 10.11138/ccmbm/2017.15.1.041
  8. Atypical femur fractures
    Cozzi Lepri A., Capone A., Del Prete A., Soderi S., Muncibì F., Civinini R.
    doi: 10.11138/ccmbm/2017.15.1.043
  9. Surgical strategies for high-energy fractures in patients with osteoporosis
    Cozzi Lepri A., Capone A., Del Prete A., Soderi S., Soderi S., Muncibì F., Innocenti M.
    doi: 10.11138/ccmbm/2017.15.1.060
  10. Sequential therapy: the way to go to prevent fragility fractures
    Gonnelli S., Alessandri M., Caffarelli C.
    doi: 10.11138/ccmbm/2017.15.1.066
  11. Atypical fractures following prolonged bisphosphonate use: a report of two cases
    Daniel-Lavee G., Nudelman P., Deltoff M., Shtarker H.
    doi: 10.11138/ccmbm/2017.15.1.070
  12. Osteoporosis treatment following a low trauma wrist fracture presenting to the Accident and Emergency Department from 2011 to 2015
    Sim Yeap S., Mat Akhir N.S., Thirunavukkarasu V., Thambiah S.C., Samsudin I.N., Zahari Sham S.Y., Balan P., Hew1 F.L., Chan S.P.
    doi: 10.11138/ccmbm/2017.15.1.074
  13. Low intestinal tract adenomatous polyps regression in FAP patients by dietary-induced erbeta upregulation
    Tonelli F., Fabbri S., Ficari F., Batignani G., Femia A.P., Caderni G., Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.079
  14. Calcific arteriolopathy beyond chronic kidney disease. The role of hemochromatosis and vitamin K antagonists
    Rodelo-Haad R.-H., De La Puebla Gimenez R.F., Ortega R., Rodriguez M., Aljama P.
    doi: 10.11138/ccmbm/2017.15.1.085
  15. Successful treatment of gonadotropin releasing hormone induced severe pregnancy and lactation-associated osteoporosis with teriparatide
    Tahsini Tekantapeh S., Khabbazi A.
    doi: 10.11138/ccmbm/2017.15.1.089
  16. Serious osteoporomalacia with vertebral fracturing progression in bariatric surgery: case report
    Bruno R., Seriolo C., Palermo A., Nardi A., Molfetta L.
    doi: 10.11138/ccmbm/2017.15.1.094
  17. Late diagnosis of angioleiomyoma of the knee: a case report
    Galanakos S.P., Mavrogenis A.F., Ignatiadis I., Macheras G.A.
    doi: 10.11138/ccmbm/2017.15.1.097
  18. A rare case of Melnick Needles syndrome. Case report and brief review of literature
    Mangaraj S., Choudhury A.K., Mishra I., Patro D., Baliarsinha A.K.
    doi: 10.11138/ccmbm/2017.15.1.100
  19. Coexistence of torus palatinus and acromegaly, an association with a common origin
    Morales J., Folleco M.
    doi: 10.11138/ccmbm/2017.15.1.103
  20. Thoracic and lumbar spinal stenosis in a patient with Klippel-Feil syndrome
    Igoumenou V.G., Karantzoulis V.G., Vazifehdan F.
    doi: 10.11138/ccmbm/2017.15.1.107
  21. Acute deafness as the first symptom of paraneoplastic syndrome: experience of two cases
    Wang X., Yu X.
    doi: 10.11138/ccmbm/2017.15.1.111
  22. Severe secondary osteoporosis in a premenopausal woman: should a specific treatment for osteoporosis be started?
    Baleanu F., Iconaru L., Karmali R., Body J.-J.
    doi: 10.11138/ccmbm/2017.15.1.115
  23. Osteogenesis imperfecta type V: clinico-radiological diagnosis of two cases in a limited resource setting
    Chawla M., Bhardwaj G.
    doi: 10.11138/ccmbm/2017.15.1.119
  24. Multi-organ extraosseous 99mTc-HMDP uptake in a case of metastatic melanoma
    Calandri E., Aretano I., Pultrone M., Liberatore M.
    doi: 10.11138/ccmbm/2017.15.1.123
  25. Bilateral transient osteoporosis of the hip. A case report and review of the literature
    Pallis D., Florin Georgiou D., Rizou S., Symeonidou Z., Sarzi-Puttini P., Troupis T., Casale R.
    doi: 10.11138/ccmbm/2017.15.1.128
  26. Effects of endocrine disrupting compounds on Vitamin D circulating levels
    Fossi C., Pampaloni B., Brandi M.L.
    doi: 10.11138/ccmbm/2017.15.1.132
Last Viewed articles: la lista degli ultimi x visitati.
  1. Pain from osteoporotic fractures: rationale of therapeutic options
    Hans G. Kress
    doi: 10.11138/ccmbm/2017.15.1.036
credits